^
    Back
    Association details:
    Biomarker:STK11 mutation
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Drug:Imfinzi (durvalumab) (PD-L1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASCO 2018
    Title:

    Somatic STK11/LKB1 mutations to confer resistance to immune checkpoint inhibitors as monotherapy or in combination in advanced NSCLC.

    Published date:
    05/16/2018
    Excerpt:
    In two independent trials evaluating D as monotherapy (CP1108/Atlantic), and in a D + T combination trial (D4190C00006), reduced ORR and shorter survival were observed in Non-SQ NSCLC pts harboring STK11 non-synonymous mutant tumors...In Non-SQ NSCLC, somatic STK11 mt may confer innate resistance to immune checkpoint inhibitors.
    DOI:
    10.1200/JCO.2018.36.15_suppl.3028
    Trial ID:
    ATLANTIC; STUDY 1108; STUDY 006